True valuation of Hemo and next steps17 Mar 2025 10:33
Hemogenyx’s current $6M market cap and lack of headroom to raise capital on the market create a significant challenge. Given the company’s recent IND approval and clinical trial initiation for HG-CT-01, this valuation is highly disconnected from its potential and suggests the market either:
1. Does not believe Hemogenyx can secure funding to progress HG-CT-01, or
2. Is unaware of the significance of its clinical-stage status, or
3. Is pricing in an imminent, highly dilutive raise at a distressed valuation.
At this valuation, a public equity raise is essentially off the table, making alternative funding sources (VC, private placement, pharma JV, or acquisition) a necessity.
⸻
1. Is the $6M Market Cap Sustainable?
No, this market cap is unsustainable for a clinical-stage biotech. Most public biotech companies with a first-in-human IND-approved asset are valued at $50M–$200M+, even at early clinical stages.
For context:
• Preclinical CAR-T biotechs (pre-IND) are typically valued at $50M–$150M.
• Clinical-stage CAR-T biotechs (post-IND) are typically valued at $100M–$500M+, depending on target and stage.
• Hemogenyx, despite reaching IND and treating its first patient, is trading at just $6M.
🔹 Key Risks at This Valuation:
• Market skepticism about funding runway—investors may assume bankruptcy risk due to lack of cash.
• Extreme dilution risk—if a market raise were possible, it would likely be at a high discount to market price.
• Investor sentiment is weak—biotech bear market conditions have disproportionately hurt small-cap companies.
🔹 Expected Correction:
• If Hemogenyx secures funding, its market cap should rapidly adjust upward (likely 10x+ from current levels).
• If no funding is secured soon, equity holders face extreme dilution risk if a distressed deal is forced.
⸻
2. How Does This Change Funding Prospects?
🔹 Equity Raise Is No Longer an Option
• Given the tiny market cap ($6M) and the fact that Hemogenyx has no headroom left to issue new shares, a market raise at a reasonable valuation is impossible.
• Any public raise at current levels would destroy existing shareholders due to massive dilution.
• Example: Raising just $10M at current market levels would require issuing 167%+ of the current market cap in new shares.
🔹 VC Funding Becomes More Critical
• VCs now have significantly more leverage because Hemogenyx must raise money to continue operations.
• A VC may offer funding, but at a deeply discounted valuation (e.g., $20M–$50M pre-money instead of $200M+).
• Hemogenyx will need to negotiate carefully to avoid excessive dilution or losing control.
🔹 Big Pharma JV/Acquisition Becomes More Likely
• Given Hemogenyx’s weak market position, a larger pharma company may see an opportunity to acquire or partner at a bargain price.
• Instead of a JV, a full acquisition ($50M–$100M+) could happen soone
Sign In
Follow the stocks
